1. St. Petersburg State Pediatric Medical University (St. Petersburg, Russian Federation)
2. Saint-Petersburg State Research Institute of Phthisiopulmonology (St. Petersburg, Russian Federation)
3. North-Western State Medical University n. a. I. I. Mechnikov (St. Petersburg, Russian Federation)

Keywords:α₁-antitrypsin deficiency,liver damage with α₁-antitrypsin deficiency,liver disease in children

Abstract:Alpha-1 antitrypsin deficiency is a frequent metabolic, genetically-associated disease in which the liver is affected, primarily in patients with a ZZ phenotype. However, according to the literature to 20 years of life, only 10-15% of patients retain or develop clinical signs of the disease. We observed 7 children with the ZZ phenotype of α₁-antitrypsin, who had a severe neonatal cholestasis, a neonatal liver syndrome, and asymptomatic moderate hyperfermentemia in young children at the initial examination. In the course of further follow-up, a tendency toward weakening of the manifestations of the disease or normalization of liver laboratory tests was observed in all, no one showed signs of progression of liver fibrosis for a period of up to 3 years. However, in children among genetic diseases in this disease, most often there is a need for a liver transplant. Diagnosis of α₁-antitrypsin deficiency is to determine its level in the blood and phenotyping. Genetic diagnosis is possible. Treatment of liver damage with α₁-AT deficiency is an unresolved problem, but in recent years new strategies have been applied when it is possible to influence individual pathological mechanisms that cause liver damage.

• References total 52 ⇓ :: .
  1. Perlmutter D. H.: “Alpha-1-antitrypsin” // In book Schiff E. R., Sorrell M. F., Maddrey W. C. (eds.) Schiff’s Diseases of the Liver, 11th edn. Oxford, Wiley-Blackwell, 2011, p. 835-867.
  2. Silverman E. K., Sandhaus R. A.: “Clinical practice. Alpha1-antitrypsin deficience” // N. Engl. J. Med., 2009, 360, p. 2749-2757.
  3. Sherlock S., Dooley J.: «Diseases of the Liver and Biliary System» // Oxford, UK: Blackwell Science Ltd a Blackwell Publishing, 11 Edition, 2002-706 p.
  4. Teckman J. H., Qu D., Perlmutter D. H.: “Molecular pathogenesis of liver disease in α₁-antitrypsin deficiency” // Hepatology, 1996, 24, p. 1504-1516.
  5. Carlson J. A., Rogers B. B., Sifers R. N. et al.”Accumulation of PiZ antitrypsin causes liver damage in transgenic mice” // Clin. Invest. 1988, 83, p. 1183-1190.
  6. Eriksson S.: “α₁-antitrypsin deficiency” // J. Hepatol., 1999, 30, suppl. 1, p. 34-39.
  7. Perlmutter D. H.: “Alpha-1-antitrypsin deficiency” // Semin. Liver Dis., 1998, 18, p. 217-222.
  8. Crystal R. G.: “α₁-Antitrypsin deficiency, emphysema, and liver disease: genetic basis and strategies for therapy” // J. Clin. Invest, 1990, 85, p. 1343-1352.
  9. Lomas D. A.: Loop sheet polymerization: the structural basis of Z α₁-antitrypsin accumulation in the liver” // Clin. Sci., 1994, 86, p. 489.
  10. Lomas D. A., Evans D. L.I., Finch J. T. et al.: “The mechanism of Z α₁-antitrypsin accumulation in the liver” // Nature, 1992, 357, p. 605-607.
  11. Qu D., Teckman J. H., Perlmutter D. H.: “α₁-Antitrypsin deficiency associated liver disease” // J. Gasroenterol., Hepatol., 1997, 12, p. 404-416.
  12. Teckman J. H., Perlmutter D. H.: “Conceptual advances in the pathogenesis and treatment of childhood liver disease” // Gasroenterology, 1995, 108, p. 1263-1279.
  13. Wu G., Whitman F., Mobments E. et al.: “A lag in intracellular degradation of mutant α₁-antitrypsin correlated with the liver disease phenotype in homozygous PiZZ α₁-antitrypsin deficiency” // Proc. Natl. Acad. Sci. USA, 1995, 91, p. 9014-9018.
  14. Geller S., Hichols W. S., Dycacio M. J. et al.; ‘Histopathology of α₁-antitrypsin liver disease in a transgenic mouse model” // Hepatology, 1990, 12, 40, p. 40-47.
  15. Geller S., Hichols W. S., Kim S. S. et al.; “Hepatocarcinogenesis is the sequel to hepatitis in Z#2 α₁-antotrypsin transgenic mice: histopatholgical and DNA ploidy studies” // Hepatology, 1994, 19, p. 389-397.
  16. Perlmutter D. H.: “Alpha-1-antitrypsin deficiency: Importance of proteasomal and autophagic degradative pathways in disposal of liver disease-associated protein aggregates” // Annu Rev. Med., 2011, 62, 4.1-4.13.
  17. Hadzic N., Quaglia A., Mieli-Vergani G.: “Hepatocellular carcinoma in a 12-year-old child with PiZZ α₁-antitrypsin deficiency” // Hepatology, 2006, 43, p. 194.
  18. Zhou H., Ortiz-Pallardo M.E., Ko Y., Fischer H-P.: “Is heterozygous alpha-1-antitrypsin deficiency type PiZ a risk factor for primary liver cancer” // Cancer, 2000, 88, p. 2668-2676.
  19. Perlmutter D.: “α₁-Antitrypsin deficiency” // In book Suchy F. J., Sokol R. J., Balistreri W. F. Liver Disease in Children. Fourth Edition. Cambridge University Press 2014, p. 400-418.
  20. Propst T., Propst A., Dietze O. et al.: “Prevalence of hepatocellular carcinoma in α₁-antitrypsin deficiency” // J. Hepatol., 1994, 21, p. 1006.
  21. Glasgow J. F.T., Lynch, Hercz A. et al.: “α₁-antitrypsin deficiency in association with both cirrhosis and chronic obstructive lung disease in two sibs” // Am. J. Med., 1973, 54, p. 181.
  22. Bakula A., Socha P., Adamowich M. et al.: “Early and late clinical presentation of α-1 antitrypcin deficiency in children” // Gut, 2005, suppl. N VII, vol. 54 - Endoscopy, 2005, suppl. N1, vol. 34, p. A 193.
  23. Francavilla R., Castellaneta S. P., Hadzic N. et al.: “α-1 antitrypsin deficiency: a 29 years experience in 241 children”. // J. Hepatol., 1999, vol. 30, suppl. № 1, p. 51.
  24. Francavilla R., Castellaneta S. P., Hadzic N. et al.: “Prognosis of alpha-1-antitrypsin deficiency-related liver disease in the era of paediatric liver transplantation”. // J. Hepatol., 2000, 32, р. 986-989.
  25. Sveger T., Eriksson S.: “The liver in adolescents with α₁-anritrypsin deficiency” // Hepatology, 1995, 22, р. 514-517.
  26. Roberts E. A.: “ The Acutely Ill Baby” // In book “Diseases of the Liver and Biliary System in Children Edited By Deirdre Kelly, 2008, Blackwell Publishing, p. 57-105.
  27. Nord K. S., Saad S., Joshi V.V, Mc Loughlin L.C.: “Concurrence of a1-antitrypsin deficiency and biliary atresia” // J. Pediatr., 1987, 111, p. 416-418.
  28. Cottrall K., Cook P. J.L., Mowat A. P.: “Neonatal hepatitis syndrome and alpha-1-antitrypsin deficiency: An epidemiological study in south-east England” // Postgrad. Med. J., 1974, 50, p. 376-380.
  29. Roberts E. A.: “The Jaundiced Baby” // In book: Kelly D.: Diseases of the Liver and Biliary System in Children. Third Edition. Blackwell Publishing, 2008, p. 57-106.
  30. Sharp H. I.: “Alpha 1-antitrypsin deficiency” // Hosp. Pract., 1971, 6(5), p. 83-96.
  31. Sveger T.: “The natural history of liver disease in α₁-antitrypsin deficient children” // Acta Paediatr. Scand., 1988, p. 847-851.
  32. Ybarguen E., Gross C. R., Savik S. K. et al.: “Liver disease in α₁-antitrypsin deficiency: prognostic indicators” // J. Pediatr., 1990, 117, p. 864-870.
  33. Sveger T.: “Liver disease in α₁-antitrypsin deficiency detected by screening of 200 000 infants” // N. Engl. J. Med., 1976, 294, 1216-1221.
  34. Brantly M.: “Laboratory diagnosis of α₁-АТ deficiency”. // In Crystal R. G. editor. Alpha 1-Antitrypsin Deficiency: Biology, Pathogenesis, Clinical Manifestations, Therapy. New York: Marcel Dekker, 1996, p. 221-226.
  35. Pitulainen E., Carlson J., Ohlsson K. et al.: “Alpha-1-antitrypsin deficiency in 26-year-old subjects: lung, liver and protease/protease inhibitor studies” // Chest 2005, 128, 2076-2081.
  36. Volpert D, Molleston J.P, Perlmutter D.H. Alpha1-antitrypsin deficiency-associated liver disease progresses slowly in some children. // J. Pediatr. Gastroenterol. Nutr., 2000б 31б, р. 258-263.
  37. Graziadi I. W., Joseph J. J., Wiesner R. H. et al: “Increased risk of chronic liver failure in adults with heterozygous α₁-antitrypsin deficiency” // Hepatology, 1998, 28, p. 1058.
  38. Pittschieler K.: “Heterozygotes and liver involvement”. // Acta Paediatr., 1994, 83 (suppl. 393), p. 21-23.
  39. Francavilla R., Castellaneta S. P., Hadzic N. et al.: “Liver disease in PiSS/PiSZ phenotype of α-1 antitrypsin deficiency”. // J. Hepatol., 1999, vol. 30, suppl. № 1, p. 164.
  40. Psacharopoulos H. T., Mowat A. P., Cook P. J. et al.: “Outcome of liver disease associated with alpha 1 antitrypsin deficiency (PiZ). Implications for genetic counselling and antenatal diagnosis” // Arch. Dis. Child., 1983, 58, p. 882-887.
  41. Nebbia G., Hadchouel M., Odievre M. et al.: “Early assessment of evolution of liver disease associated with alpha 1-antitrypsin deficiency in childhood” // J. Pediatr., 1983, 102, p. 661-665.
  42. Ibarguen E, Gross C.R, Savik S.K, Sharp H.L. Liver disease in alpha-1-antitrypsin deficiency: prognostic indicators. // J. Pediatr., 1990, 117, 864-870.
  43. Prachalias A. A., Kalife M., Francavilla R. et al.: “Liver transplantation for alpha-1-antitrypsin deficiency in children” // Transpl. Int., 2000, 13, 207-210.
  44. Teckman J. H., Perlmutter D. H.: “Retention of mutant α₁-antitrypsin Z in endoplasmatic reticulum is associated with an autophagic response” // Am. J. Physiol., 2000, 279, G961-G974.
  45. Lang T., Mühlbauer M., Strobelt M. et al.: “Alpha-1-antitrypsin deficiency in children: liver disease is not reflected by low serum levels of alpha-1-antitrypsin a study on 48 pediatric patients” // Eur. J. Med. Res., 2005, 10, p. 509-514.
  46. Teckman J. H.: “Lack of effect of oral 4-phenylbutyrate on serum alpha-1-antitrypsin in patients with alpha-1-antitrypsin deficiency: preliminary study” // J. Pediatr. Gastroenterol. Nutr., 2004, 39, 34-37.
  47. Burrows J. A., Willis L. K., Perlmutter D. H.: “Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: a potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency” // Proc. Natl. Acad. Sci. U S A 2000, 97, 1796-1801.
  48. Marcus N. Y., Perlmutter D. H.: “Glucosidase and mannosidase inhibitor mediate increased secretion of mutant α₁-antitrypsin Z” // Z. J. Biol. Chem., 2000, 275, 1987-1992.
  49. Hidvegi T., Ewing M., Hale P. Et al.: “An autophagy-enhancing drug promotes degradation of mutant α1-antitrypsin Z and reduces hepatic fibrosis” // Science, 2010, 329, p. 229-232.
  50. Kemmer N., Kaiser T., Zacharias V. et al.: “Alpha-1-antitrypsin deficiency: outcomes after liver transplantation” // Transplant. Proc., 2008, 40, 1492-1494.
  51. Vennarecci G., Gunson B. K., Ismail T. et al.: “Transplantation for end stage liver disease related to alpha 1 antitrypsin” // Transplantation, 1996, 61, p. 1488-1495.
  52. Van Furth r., Kramps J. A., van der Putten A. B. et al.: “Change in alpha-1-antitrypsin phenotype after orthotopic liver transplant” // Clin. Exp. Immunol., 1986, 66, p. 669.).

Full text is published :
LIVER DISEASE IN CHILDREN CAUSED BY Α1-ANTITRYPSIN DEFICIENCY. Experimental and Clinical Gastroenterology Journal. 2018;150(02):89-99
Read & Download full text

1. Donetsk National Medical University (Donetsk, Ukraine)

Keywords:non-alcoholic fatty liver disease,non-alcoholic steatohepatitis,treatment,diet,physical activity

Abstract:The article presents literature data of recent years on the relevance of the problem of non-alcoholic fatty liver disease. The data on the role of physical activity, decrease in body weight upon this pathology are analyzed. Peculiar attention is paid to nutrition recommendations with variants of hypocaloric diets. An algorithm for changing lifestyle, increasing physical activity and dietary nutrition is presented, aimed at reducing body weight and treating non-alcoholic fatty liver disease.

• References total 48 ⇓ :: .
  1. Ivashkin V. Т. Clinical variants of metabolic syndrome / V. Т. Ivashkin, О. М. Drapkina, О. N. Кorneeva. – Мoscow: Меd. Inform. Agency, 2011. – 220 p.
  2. Overweight and obesity: consequences for health and life, modern guidelines on reaching and keeping the normal body mass / V. G. Perederiy, S. М. Тkach, V. I. Кutovoy, М. М. Rotter. – Kiev: Start-98, 2013. – 240 p.
  3. Tkach S. M. Modern pharmacotherapy of non-alcoholic fatty liver disease/ S. М. Тkach, Т. Y. Yuzvenko, Т. L. Cheverda // Health of Ukraine. – 2017. – No 18. – P. 68–71.
  4. Shvets О. V. Dietary recommendations for patients with disseminated compensated liver diseases / О. V. Shvets // Health of Ukraine. – 2016. – No 8. – P. 3.
  5. Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort / V. W. Setiawan, L. R. Wilkens, S. C. Lu [et al.] // Gastroenterology. - 2015. - Vol. 148. - P. 118-125.
  6. Barb D. Pharmacological management of nonalcoholic fatty liver disease / D. Barb, P. Portillo-Sanchez, K. Cusi // Metabolism. - 2016. - Vol. 65. - P. 1183-1195.
  7. Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach / S. Bellentani, R. Dalle Grave, A. Suppini [et al.] // Hepatol. - 2008. - Vol. 47. - P. 746-754.
  8. Bird’s eye view of nonalcoholic fatty liver disease - an insulin resistant state / T. P. Manopriya, A. Elshaari Faraj, S. Dhastagir, A. Sheriff // Acta Medica Saliniana. - 2010. - Vol. 39, No 1. - P. 1-5.
  9. Coffee and herbal tea consumption is associated with lower liver stiffness in the general population: the Rotterdam study / L. J. M. Alferink, J. Fittipaldi, J. C. Kiefte-de Jong [et al.] // J. Hepatol. - 2017. - Vol. 67, No 2. - P. 339-348.
  10. Coffee drinking and alcoholic and nonalcoholic fatty liver diseases and viral hepatitis in the multiethnic cohort / V. W. Setiawan, J. Porcel, P. Wei [et al.] // Clin. Gastroenterol. Hepatol. - 2017. - Vol. 15, No 8. - P. 1305-1307.
  11. Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis / F. Bravi, C. Bosetti, A. Tavani [et al.] // Clin. Gastroenterol. Hepatol. - 2013. - Vol. 11. - P. 1413-1421.
  12. Development of new fatty liver, or resolution of existing fatty liver, over 5 year of follow up: effect of exercise / K.-S. Sung, S. Ryu, J.-Y. Lee [et al.] // J. Hepatol. - 2016. - Vol. 65. - P. 791-797.
  13. The diagnosis and management of nonalcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology / N. Chalasani, Z. Younossi, J. E. Lavine [et al.] // Gastroenterology. - 2012. - Vol. 142, No 7. - P. 1592-1609.
  14. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease / G. Marchesini, C. P. Day, J.-F. Dufour [et al.] // J. Hepatol. - 2016. - Vol. 64, No 6. - P. 1388-1402.
  15. Effects of dark chocolate on NOX-2-generated oxidative stress in patients with non-alcoholic steatohepatitis / L. Loffredo, M. Del Ben, L. Perri [et al.] // Aliment. Pharmacol. Ther. - 2016. - Vol. 44, No 3. - P. 279-286.
  16. The effects of DASH diet on weight loss and metabolic status in adults with non-alcoholic fatty liver disease: a randomized clinical trial / M. Razavi Zade, M. H. Telkabadi, F. Bahmani [et al.] // Liver Int. - 2016. - Vol. 36, No 4. - P. 563-571.
  17. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group / F. M. Sacks, L. P. Svetkey, W. M. Vollmer [et al.] // N. Engl. J. Med. - 2001. - Vol. 344. - P. 3.
  18. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis / S. Watanabe, E. Hashimoto, K. Ikejima [et al.] // J. Gastroenterol. - 2015. - Vol. 50, No 4. - P. 364-377.
  19. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis / S. Keating, D. Hackett, J. George, N. Johnson // J. Hepatol. - 2012. - Vol. 57. - P. 157-166.
  20. Exercise-based interventions for nonalcoholic fatty liver disease: a meta-analysis and meta-regression / L. A. Orci, K. Gariani, G. Oldani [et al.] // Clin. Gastroenterol. Hepatol. - 2016. - Vol. 14, No 10. - P. 1398-1411.
  21. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013 / M. Ng, T. Fleming, M. Robinson [et al.] // Lancet. - 2014. - Vol. 384, No 9945. - P. 766-781.
  22. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels / P. Portillo-Sanchez, F. M. Bril, M. Maximos [et al.] // J. Clin. Endocrinol. Metab. - 2015. - Vol. 100. - P. 2231-2238.
  23. A highsucrose isocaloric pair-fed model induces obesity and impairs NDUFB6 gene function in rat adipose tissue / A. Lomba, F. I. Milagro, D. F. Garcia-Diaz [et al.] // J. Nutrigenet. Nutrigenomics. - 2009. - Vol. 2. - P. 267-272.
  24. Inadequate dietary magnesium intake increases atherosclerotic plaque development in rabbits / J. L. King, R. J. Miller, J. P. Blue Jr. [et al.] // Nutr. Res. - 2009. - Vol. 29. - Vol. 343-349.
  25. Increased intake of vegetables, but not fruit, reduces risk for hepatocellular carcinoma: a meta-analysis / Y. Yang, D. Zhang, N. Feng [et al.] // Gastroenterology. - 2014. - Vol. 147. - P. 1031-1042.
  26. Insulin sensitivity increase after calcium supplementation and change in intraplatelet calcium and sodium-hydrogen exchange in hypertensive patients with type 2 diabetes / M. I. Pikilidou, A. N. Lasaridis, P. A. Sarafidis [et al.] // Diabet. Med. - 2009. - Vol. 26. - P. 211-219.
  27. Keating S. E. Exercize in NAFLD: just do it / S. E. Keating, L. A. Adams // J. Hepatol. - 2016. - Vol. 65. - P. 671-673.
  28. Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients / L. Bozzetto, A. Prinster, G. Annuzzi [et al.] // Diabetes Care. - 2012. - Vol. 35. - P. 1429-1435.
  29. Loomba R. The global NAFLD epidemic / R. Loomba, A. J. Sanyal // Nat. Rev. Gastroenterol. Hepatol. - 2013. - Vol. 10, No 11. - P. 686-690.
  30. Mediterranean diet and hepatocellular carcinoma / F. Turati, D. Trichopoulos, J. Polesel [et al.] // J. Hepatol. - 2014. - Vol. 60. - P. 606-611.
  31. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with nonalcoholic fatty liver disease / M. C. Ryan, C. Itsiopoulos, T. Thodis [et al.] // J. Hepatol. - 2013. - Vol. 59, No 1. - P. 138-143.
  32. Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study / C. P. Wen, J. P. Wai, M. K. Tsai [et al.] // Lancet. - 2011. - Vol. 378. - P. 1244-1253.
  33. Non-alcoholic fatty liver disease is not associated with a lower health perception / L. Mlynarsky, D. Schlesinger, R. Lotan [et al.] // World J. Gastroenterol. - 2016. - Vol. 22. - P. 4362-4372.
  34. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States / R. J. Wong, M. Aguilar, R. Cheung [et al.] // Gastroenterology. - 2015. - Vol. 148, No 3. - P. 547-555.
  35. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men / J. M. Chan, E. B. Rimm, G. A. Colditz [et al.] // Diabetes Care. - 1994. - Vol. 17, No 9. - P. 961-969.
  36. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial / S. A. Harrison, W. Fecht, E. M. Brunt, B. A. Neuschwander-Tetri // Hepatology. - 2009. - Vol. 49, No 1. - P. 80-86.
  37. The possible role of Ca2+ on the activation of microsomal triglyceride transfer protein in rat hepatocytes / H. J. Cho, H. C. Kang, S. A. Choi [et al.] // Biol. Pharm. Bull. - 2005. - Vol. 28. - P. 1418-1423.
  38. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study / E. M. Koehler, E. P. Plompen, J. N. Schouten [et al.] // Hepatology. - 2016. - Vol. 63, No 1. - P. 138-147.
  39. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients / G. Targher, L. Bertolini, R. Padovani [et al.] // Diabetes Care. - 2007. - Vol. 30. - P. 1212-1218.
  40. Prevention of diabetes with Mediterranean diets: a subgroup analysis of a randomized trial / J. Salas-Salvado, M. Bullo, R. Estruch [et al.] // Ann. Intern. Med. - 2014. - Vol. 160, No 1. - P. 1-10.
  41. Relationship of sitting time and physical activity with non-alcoholic fatty liver disease / S. Ryu, Y. Chang, H. S. Jung [et al.] // J. Hepatol. - 2015. - Vol. 63. - P. 1229-1237.
  42. Rinella M. E. Nonalcoholic fatty liver disease: a systematic review / M. E. Rinella // JAMA. - 2015. - Vol. 313. - P. 2263-2273.
  43. Role of insulin resistance and diabetes in the pathogenesis and treatment of nonalcoholic fatty liver disease / P. Y. Portillo, S. Yavuz, F. Bril, K. Cusi // Curr. Hepatol. Rep. - 2014. - Vol. 13. - P. 159-170.
  44. Unwin N. The IDF Diabetes Atlas: providing evidence, raising awareness and promoting action / N. Unwin, D. Gan, D. Whiting // Diabetes. - Res. Clin. Pract. - 2010. - Vol. 87, No l. - P. 2-3.
  45. Weight gain as a risk factor for clinical diabetes mellitus in women / G. A. Colditz, W. C. Willett, A. Rotnitzky [et al.] // Ann. Intern. Med. - 1995. - Vol. 122, No 7. - P. 481-486.
  46. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis / E. Vilar-Gomez, Y. Martinez-Perez, L. Calzadilla-Bertot [et al.] // Gastroenterology. - 2015. - Vol. 149, No 2. - P. 367-378.
  47. World Health Organization (WHO), Fact Sheet No 311 (updated March 2013) //www.who.int/mediacentre/factsheets/fs311/en/
  48. Zelber-Sagi S. Evidence for lifestyle and weight management for the progression of NAFLD, metabolic or cardiovascular disease / S. Zelber-Sagi. - EASL postgraduate course: non-alcoholic fatty liver disease. - The Netherlands (Amsterdam), 2017. - P. 49-56.

Full text is published :
MODERN VIEWS ON NUTRITION AND PHYSICAL ACTIVITY IN THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE. Experimental and Clinical Gastroenterology Journal. 2018;150(02):100-109
Read & Download full text

1. Public budgetary educational institution of higher education “North-western State Medical University named after I. I. Mechnikov” of the Ministry of Healthcare of the Russia (St. Petersburg, Russian Federation)
2. Health Сare Unit of State Unitary Enterprise “Vodokanal of St. Petersburg” (St. Petersburg, Russian Federation)

Keywords:cholelithiasis,cholecystocardial syndrome,cholecystectomy

Abstract:The article presents data on the prevalence, clinical manifestations of cholelithiasis. The connection between the pathology of the biliary tract and changes in the activity of the cardiovascular system was noted. A clinical picture of cholecystocardial syndrome (CCS) and tactics of disease management with this pathology are described. The case of own clinical observation of a patient with CCS illustrates the published literature data.

• References total 14 ⇓ :: .
  1. Popova IR, Pavlov Ch. S., Glushchenkov DV, Drapkyna OM, Ivashkin VT The prevalence of the liver disease and gallbladder disorders in patients with body weight and obesity. Klinicheskaya Medicina [Clinical Medicine] 2012; 90 (10):38–43 (in Russian)
  2. Stinton L. M., Shaff er E. A. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut Liver, 2012; 6 (2): 172–87.
  3. Radchenko VG, Shabrov A. V., Zinovieva E. N., Sinkin S. I. Zabolevaniya pecheni i zhelchevyvodyashchikh putey: rukovodstvo dlya vrachey [Diseases of the liver and bile ducts: a guide for doctors]. SPb: SpetsLit, 2011. 526 p. ISBN978–5–299–00348–2 (in Russian)
  4. Recommendations of the Russian gastroenterological association for the diagnosis and treatment of gallstone disease. RZHGGK, 2016; 3: 64–80 (in Russian)
  5. Skvortsova TE, Sitkin SI, Radchenko VG, Seliverstov PV, Tkachenko EI Zhelchnokamennaya bolezn'. Sovremennyye podkhody k diagnostike, lecheniyu i profilaktike: posobiye dlya vrachey [Gallstone disease. Modern approaches to diagnosis, treatment and prevention: a manual for doctors]. Moscow: Forte print, 2013. 32 p. (in Russian)
  6. Kazyulin AN Masks of biliary dysfunction. Eksperimental'naya i klinicheskaya gastroenterologiya [Experimental and clinical gastroenterology] 2015; 114 (2): 71–81 (in Russian)
  7. Gubergrits NB, Lukashevich GM Zhelchnokamennaya bolezn': ot S. P. Botkina k sovremennosti [Gallstone disease: from SP Botkin to the present]. Moscow: 4TE Art, 2011. 48 p (in Russian)
  8. Vetshev PS, Nogtev PV Cholecystokardial syndrome – a myth or reality. Khirurgiya. Zhurn. im. N. I. Pirogova [Surgery. Jour. them. NI Pirogov] 2005; 3: 59–64 (in Russian)
  9. Trukhan DI, Tarasova LV, Bagisheva NV Pain in the thorax associated with diseases of the digestive system Dnevnik Kazanskoy meditsinskoy shkoly [Diary of the Kazan Medical School] 2014;4: 49–53 (in Russian)
  10. Gridnev AE Cholecystocardial syndrome. [Electronic resource] Access mode: / URL: http: // health-ua.com/articles/1518.
  11. Kazyulin A. N. Pain syndrome in diseases of the biliary tract Meditsinskiy vestnik [Medical Bulletin] 2012; 17–18: 17 (in Russian)
  12. D. I. Trukhan. Differential diagnosis of pain in the chest: in focus – diseases of the digestive system Consilium Medicum. 2015; 1: 63–67 (in Russian)
  13. Styazhkina SN, Sayfullina AR, Zagidulina SI Diagnosis of acute cholecystitis. Differential Diagnosis of Cholecystocardial Syndrome Sinergiya nauk [Synergy of Sciences] 2017; 10: 823–827 (in Russian)
  14. EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. Journal of Hepatology, 2016. Juli; Vol. 65 (1): 146–181.

Full text is published :
CHOLECISTOCARDIAC SYNDROME: TROUBLES OF DIFFERENTIAL DIAGNOSIS. Experimental and Clinical Gastroenterology Journal. 2018;150(02):110-114
Read & Download full text

1. Volgograd State Medical University (Volgograd, Russian Federation)
2. Astrakhan State Medical University (Astrakhan, Russian Federation)

Keywords:Caroli’s disease, cholangiocarcinoma, hepatectomy, Caroli’s syndrome, polycystic kidney disease, bile ducts, abdominal pain, cholangitis, liver transplantation, endoscopic retrograde cholangiopancreatography

Abstract:This review focuses on the clinical picture, approaches to diagnosis and therapy of Caroli’s disease and Caroli’s syndrome.

• References total 27 ⇓ :: .
  1. Mabrut JY, Kianmanesh R, Nuzzo G, Castaing D, Boudjema K, Létoublon C, et al. Surgical management of congenital intrahepatic bile duct dilatation, Caroli’s disease and syndrome: longterm results of the French Association of Surgery Multicentre Study. Ann Surg. 2013; 258:713–721.
  2. Zhong-Xia Wang, Yong-Gang Li, Rui-Lin Wang, et al. Clinical classification of Caroli’s disease: an analysis of 30 patients. HPB (Oxford). 2015 Mar; 17(3): 278–283.
  3. Man Mohan Harjai, RK Bal, SK Mohantyet al. Caroli Disease And Caroli Syndrome. Med J Armed Forces India. 2017 Apr; 55(2): 155–156.
  4. Min Hye Jang, Yoon Jin Lee, and Haeryoung Kim. Intrahepaticcholangiocarcinoma arising in Caroli’s disease. Clin Mol Hepatol. 2014 Dec; 20(4): 402–405.
  5. Ko JS, Yi NJ, Suh KS, Seo JK. Pediatric liver transplantation for fibropolycystic liver disease. Pediatr Transplant. 2012; 16:195–200.
  6. Sato Y, Ren XS, Nakanuma Y. Caroli’s disease: current knowledge of its biliary pathogenesis obtained from an orthologous rat model. Int J Hepatol. 2012; 2012:107945.
  7. Dae Hoe Gu, Min Seon Park, Chang Ho Jung. Caroli’s disease misdiagnosed as intraductal papillary neoplasm of the bile duct. Clin Mol Hepatol. 2015 Jun; 21(2): 175–179.
  8. Zhang DY, Ji ZF, Shen XZ, Liu HY, Pan BJ, Dong L. Caroli’s disease: a report of 14 patients and review of the literature. J Dig Dis. 2012; 13:491–495.
  9. Srinath A, Shneider BL. Congenital hepatic fibrosis and autosomal recessive polycystic kidney disease. J Pediatr Gastroenterol Nutr. 2012; 54:580–587.
  10. Eiko Hasegawa, Naoki Sawa, Junichi Hoshino. Recurrent Cholangitis in a Patient with Autosomal Dominant Polycystic Kidney Disease (ADPKD) and Caroli’s Disease. Intern Med. 2016 Oct 15; 55(20): 3009–3012.
  11. Suwabe T, Ubara Y, Sumida K, et al. Clinical features of cyst infection and hemorrhage in ADPKD: new diagnostic criteria. ClinExpNephrol 16: 892–902, 2012.
  12. Bergmann C. ARPKD and manifestations of ADPKD: the original polycystic kidney disease and phenocopies. Pediatr Nephrol 30: 15–30, 2015.
  13. Harring TR, Nguyen NT, Liu H, Goss JA, O’Mahoney CA. Caroli disease patients have excellent survival after liver transplant. J Surg Res 177: 365–372, 2012.
  14. Monitoring Editor: Alexander Muacevic and John R Adler. Caroli’s Disease as a Cause of Chronic Epigastric Abdominal Pain: Two Case Reports and a Brief Review of the Literature. Cureus. 2017 Sep; 9(9): e1701.
  15. Yonem O, Bayraktar Y. Clinical characteristics of Caroli’s Clinical characteristics of Caroli’s syndrome. World J Gastroenterol 2007; 13(13): 1934–1937.
  16. Ros E., Navarro S., Bru C., et al. Ursodeoxycholic acid treatment of primary hepatolithiasis in Caroli’s syndrome. Lancet 1993, 342:404–406.
  17. Cabral Correia P, Morgado B. Caroli’s Disease as a Cause of Chronic Epigastric Abdominal Pain: Two Case Reports and a Brief Review of the Literature. September 20, 2017. Cureus 9(9): e1701.
  18. Tsunoda T, Furui J, Yamada M, et al. Caroli’s disease associated with hepatolithiasis: a case report and review of the Japanese literature. Gastroenterol Jpn 1991, 26:74–79.
  19. Caroli’s disease: radiologic spectrum with pathologic correlation. Levy AD, Rohrmann CA Jr, Murakata LA, Lonergan GJ AJR Am J Roentgenol. 2002 Oct; 179(4):1053–7.
  20. Kassahun WT, Kahn T, Wittekind C, et al. Caroli’s disease: liver resection and liver transplantation. Experiencein 33 patients. Surgery. 2005, 138:888–898.
  21. Morozov D. A., Gusev A. A., Pimenova E. S. Bile Duct Cysts: Modern Aspects of Surgical Treatment and Clinical Observationof a Rare Case. Voprosy sovremennoi pediatrii – Current Pediatrics. 2015; 14 (3): 412–415.
  22. Levitan B. N., Umerova A. R., Larina N. N. Chronicheskaya patologiya pecheni I kishechnii microbiocenoz (kliniko-patogeneticheskie aspekty). Astrahan´, 2010, 135 s.
  23. Levitan B. N., Sal´nikova G.G., Umerova A. R. Klinicheskaya effektivnost´ plazmafereza pri sindromah endogennoi intoksikacii i vnutripechenochnogo holestaza pri hronicheskih diffuznih zabolevaniyah pecheni // Astrahanskii medicinskii zhurnal. 2003. T.4. N4. S.6–11.
  24. Ivashkin V. T., Shirokova E. N., Maevskaya M. V. Klinicheskie rekomendacii Rossiiskoi gastroenterologicheskoi associacii i Rossiiskogo obshestva po izucheniyu pecheni po diagnostike i lecheniyu cholestaza // Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2015. T.25. N2. S.41–57.
  25. Vnutrennie bolezni / V. V. Skvortsov. – Moskva: Eksmo, 2010. – 1077 s.
  26. Skvortsov V. V., Tumarenko A. V. Klinicheskaya gastroenterologiya: kratkii kurs / V. V. Skvortsov, A. V. Tumarenko. – Sankt-Peterburg: Speclit, 2015. – 183 s.
  27. Kozlova I. V., Pahomova A. L. Prakticheskaya gastroenterologiya. Rukovodstvo dlya vrachei: uchebnoye posobie dlya sistemi poslevuzovskogo professional´nogo obrazovaniya vrachei / I. V. Kozlova, A. L. Pahomova. Moskva: Drofa, 2010. Tom 2. 345 s.

Full text is published :
DISEASE AND CAROLI’S SYNDROME: CURRENT STATE OF THE PROBLEM. Experimental and Clinical Gastroenterology Journal. 2018;150(02):115-120
Read & Download full text